AstraZeneca to move U.S. listing from Nasdaq to direct NYSE ordinary-share trading

AstraZeneca said it will voluntarily delist its U.S. American Depositary Shares and certain debt securities from the Nasdaq Stock Market and will implement a direct listing of its ordinary shares and specified debt securities on the New York Stock Exchange. The company set a precise timetable: Nasdaq listings will cease after the market close on January 30, 2026, and trading of ordinary shares and the included debt securities on the NYSE is expected to begin on February 2, 2026. The AZN ticker will be retained on the NYSE.

The move is part of a shareholder-approved plan AstraZeneca is calling the Harmonised Listing Structure, which will result in the company’s ordinary shares being traded directly on three major exchanges: the London Stock Exchange, Nasdaq Stockholm and the NYSE. Under the current depositary architecture, each American Depositary Share represents two ordinary shares; following the change, U.S. investors will shift from buying two-for-one ADS instruments to trading AstraZeneca’s $0.25 ordinary shares directly on the NYSE.

AstraZeneca framed the switch as a simplification of a multi-market trading setup intended to reduce complexity for investors and expand the company’s reach among global capital providers. The company chair said the harmonised global listing "will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future." The company also included certain debt securities in the transfer, including subsidiary-issued instruments that are guaranteed by the parent company, moving those listings from Nasdaq to the NYSE alongside the equity.

For markets and investors, the change is aimed at improving transparency and smoothing settlement mechanics for international trading. Direct listings of ordinary shares eliminate a layer of depositary intermediation and associated fees and can make pricing and corporate actions easier to follow for investors that transact on U.S. exchanges. Retaining the AZN ticker will preserve continuity for index providers, broker systems and investor tracking, reducing the potential for confusion at the point of transfer.

Liquidity patterns may shift as trading interest rebalances from ADS instruments to on-exchange ordinary shares in New York. Because the company’s shares will continue to trade on the LSE and Nasdaq Stockholm, the transition creates a genuine three-exchange listing rather than closing off European venues. That multi-venue presence could support cross-border trading and arbitrage flows, while also broadening the pool of U.S.-domiciled institutional investors able to hold ordinary shares directly.

Operationally, the timetable leaves a narrow interval between the Nasdaq cessation and NYSE commencement intended to preserve continuity. Market participants will watch volumes around January 30 and February 2 for signs of temporary volatility or widened spreads as order flow migrates. Debt holders will likewise see their U.S.-listed securities move venues, a shift that could influence secondary-market liquidity for guaranteed instruments.

The change underscores a broader trend of large global firms seeking to simplify cross-listing arrangements to make equity and debt instruments more accessible to a global investor base. AstraZeneca’s Harmonised Listing Structure is intended to reduce complexity and align trading across major financial centres while maintaining the company’s long-standing ties to its London and Stockholm markets.